---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-22-000071"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:09:11.059224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q3 revenue $177.4M (+19% YoY); guides FY2022 revenue $650-680M

## Summary
- GAAP net earnings $1.7M ($0.03 diluted EPS); adjusted op earnings $25.4M vs $43.3M prior year.
- Total revenues $177.4M (+19% YoY); Qelbree sales $18.3M (+65% QoQ) with 94,328 prescriptions.
- FY 2022 guidance raised: total revenue $650-680M (from $640-680M) and GAAP op earnings $35-45M (from $20-40M).
- FDA issued CRL for SPN-830 (apomorphine device; Parkinson's); no new efficacy/safety trials needed but device and quality info required; Class 2 review timeline (6 months).

## SEC filing metadata
- accession: 0001356576-22-000071
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/0001356576-22-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/supn-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-22-000071
- JSON: https://secwatch.observer/filing/0001356576-22-000071.json
- Plain text: https://secwatch.observer/filing/0001356576-22-000071.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. updated its third quarter ended September 30, 2022 guidance (raised).
  - Period: third quarter ended September 30, 2022
  - Guidance: raised
  - Result: reported results
  source text: Supernus Announces Third Quarter 2022 Financial Results • Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 • Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously • Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previously
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/0001356576-22-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.